Stocks and Investing Stocks and Investing
Fri, April 30, 2021

Brian Abrahams Maintained (VRTX) at Buy with Decreased Target to $262 on, Apr 30th, 2021


Published on 2024-10-27 16:29:13 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $265 to $262 on, Apr 30th, 2021.

Brian has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021


These are the ratings of the 5 analyists that currently disagree with Brian


  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $302 on, Wednesday, April 21st, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $252 on, Tuesday, April 20th, 2021
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021

Contributing Sources